FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study  

作　　者：In Rae Cho Huapyong Kang Jung Hyun Jo Hee Seung Lee Moon Jae Chung Jeong Youp Park Seung Woo Park Si Young Song Chansik An Mi-Suk Park Seungmin Bang 

机构地区：[1]Department of Internal Medicine,International Saint Mary’s Hospital,Catholic Kwandong University College of Medicine,Incheon 22711,South Korea [2]Department of Medicine,Yonsei University Graduate School,50-1 Yonsei-ro,Seoul 03722,South Korea [3]Division of Gastroenterology,Department of Internal Medicine,Yonsei University College of Medicine,50-1 Yonsei-ro,Seoul 03722,South Korea [4]Department of Radiology,Yonsei University College of Medicine,50-1 Yonsei-ro,Seoul 03722,South Korea

出　　处：《World Journal of Gastrointestinal Oncology》2020年第2期182-194,共13页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：BACKGROUND FOLFIRINOX and gemcitabine plus nab-paclitaxel(Gem+nabPTX)were recently introduced for metastatic pancreatic cancer treatment.However,studies that compared these two regimens and studies in Asian populations are lacking.AIM To compare the treatment outcomes of FOLFIRINOX and Gem+nabPTX regimen for metastatic pancreatic cancer treatment in Korean population.METHODS Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX(n=86)or Gem+nabPTX(n=81)as the first-line since January 2015 were identified using the Severance Hospital Pancreatic Cancer Cohort Registry.Treatment efficacy,treatment-related adverse events and economic aspects were compared.RESULTS Patients in the FOLFIRINOX group were significantly younger(54 vs 65 years;P<0.001)and had better performance statuses at diagnosis.The median overall survival(10.7 vs 12.1 mo;P=0.157),progression-free survival(8.0 vs 8.4 mo;P=0.134),and objective response rates(33.7%vs 46.9%;P=0.067)were not significantly different when compared with Gem+nabPTX group.Grade≥3 neutropenia and gastrointestinal adverse events were more common in the FOLFIRINOX group.The drug costs of both regimens were similar.CONCLUSION Treatment efficacy and economic burdens were comparable between the two regimens.But,the details of adverse event were different.Gem+nabPTX regimen might be considered preferentially in certain conditions.BACKGROUND FOLFIRINOX and gemcitabine plus nab-paclitaxel(Gem + nab PTX) were recently introduced for metastatic pancreatic cancer treatment. However, studies that compared these two regimens and studies in Asian populations are lacking.AIM To compare the treatment outcomes of FOLFIRINOX and Gem + nab PTX regimen for metastatic pancreatic cancer treatment in Korean population.METHODS Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX(n = 86) or Gem + nab PTX(n = 81) as the first-line since January 2015 were identified using the Severance Hospital Pancreatic Cancer Cohort Registry.Treatment efficacy, treatment-related adverse events and economic aspects were compared.RESULTS Patients in the FOLFIRINOX group were significantly younger(54 vs 65 years; P< 0.001) and had better performance statuses at diagnosis. The median overall survival(10.7 vs 12.1 mo; P = 0.157), progression-free survival(8.0 vs 8.4 mo; P =0.134), and objective response rates(33.7% vs 46.9%; P = 0.067) were not significantly different when compared with Gem + nab PTX group. Grade ≥ 3 neutropenia and gastrointestinal adverse events were more common in the FOLFIRINOX group. The drug costs of both regimens were similar.CONCLUSION Treatment efficacy and economic burdens were comparable between the two regimens. But, the details of adverse event were different. Gem + nab PTX regimen might be considered preferentially in certain conditions.

关 键 词：Pancreatic cancer CHEMOTHERAPY FOLFIRINOX GEMCITABINE Nabpaclitaxel SURVIVAL 

分 类 号：R735.9[医药卫生—肿瘤]